Regeneron Pharmaceuticals and Intellia Therapeutics announced they are widening the scope of their gene editing collaboration made four years ago to include projects for the treatment of hemophilia. As part of the expanded deal, Regeneron will pay Intellia $100 million in exchange for its use of the latter's cell re-engineering technology for the development and commercialization of hemophilia therapies.
Gene editing partnership broadened to include hemophilia
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.